Skip to content

Bioventus BVS Asset turnover

Asset turnover at other companies

Stryker logo
StrykerSYK
0.5×0.0×
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
0.4×0.0×
Medtronic logo
MedtronicMDT
0.4×0.0×
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
0.9×+0.1×
Artivion logo
ArtivionAORT
0.5×+0.1×
Globus Medical logo
Globus MedicalGMED
0.6×+0.1×

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Calculated from Bioventus’s reported figures.

Based on trailing twelve months.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's asset turnover?
Bioventus (BVS) reported asset turnover of 0.9× in Q1 2026.
How has Bioventus's asset turnover changed year-over-year?
Bioventus's asset turnover increased by 12.4% year-over-year, from 0.8× to 0.9×.
What is the long-term trend for Bioventus's asset turnover?
Over 4 years (2021 to 2025), Bioventus's asset turnover has grown at a 12.6% compound annual growth rate (CAGR), from 0.5× to 0.8×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.